PFE · Earnings call · 2026Q3T · Full report

Oncology Portfolio Growth

PFIZER INC · 2026-11-03 · Importance 52 · Surprise 56

Pfizer said its legacy Seagen portfolio grew 39% year over year in the U.S., driven by Padcev, and that acquired products overall grew 37% operationally. Management said combining Seagen medicines with Pfizer’s commercial reach has expanded its presence and expertise in the oncology community. Padcev was also described as reinforcing its role with pembrolizumab in muscle-invasive bladder cancer, while Pfizer has started a bladder-sparing study and plans a Phase 3 Padcev–gedatolisib trial.

Key facts

• Pfizer's legacy Seagen portfolio grew 39% year over year in the U.S. in Q3 2026, driven by Padcev.
• Pfizer's CEO said the Street forecast $5 billion for a competing product and $600 million for Pfizer's Elrexfio, and said Pfizer aspires for Elrexfio to have a profile similar in efficacy and better in tolerability and side effects; that profile remains to be proven.